March 17th, 2013

Introducing The Rowboat
Quite Possibly The Holy Grail of Investing.
Step 1: Sell the Put
( This is a Cash Covered Put, I have to have enough Cash to buy 100 shares per contract if the option is exercised, this is also
my maximum risk.)
EXAS @ $ 10.09
Sell To Open EXAS April 2013 $7.00 Put @ Market
Currently .60c bid / .65c time
8.57% return in 32 days
How to do this trade and commentary Video:
(Sign up for Auto-trading and have this trade done for you automatically)
http://youtu.be/RQKuPVrB6O4
Exact Sciences Corporation, a molecular diagnostics company, focuses on
developing diagnostic screening products for the early detection and prevention
of colorectal pre-cancer and cancer. The company develops the Cologuard, a
non-invasive stool-based DNA colorectal cancer screening test that is designed
to detect pre-cancerous lesions or polyps, and each of the four stages of
colorectal cancer. Its Cologuard test includes proprietary and patented methods
that isolate and analyze the human DNA that are shed into stool every day from
the exfoliation of cells that line the colon; and also protein marker to detect blood
in the stool, utilizing an antibody-based fecal immunochemical test.
The company’s stool-based DNA colorectal cancer screening technology also
focuses on the inflammatory bowel disease. It has collaboration, license, and
purchase agreement with Genzyme Corporation, as well as with Mayo Clinic for
developing tests to detect other gastro-intestinal cancers, primarily esophageal
and pancreatic cancer. Exact Sciences Corporation was founded in 1995 and is
headquartered in Madison, Wisconsin.
Exact Sciences Corporation
441 Charmany Drive
Madison, WI 53719
Phone: 608-284-5700
Fax: 608-284-5701
Website: http://www.exactsciences.com
UNXL @ $27.97
Sell To Open UNXL April 2013 $22.50 Put @ Market
Currently 1.40c bid / 1.48c time
6.22% return in 32 days

How to do this trade and commentary Video:

(Sign up for Auto-trading and have this trade done for you automatically)

http://youtu.be/EqPhsu8MbWQ

Uni-Pixel, Inc. delivers performance engineered films to the display, touch screen, and flexible electronics market segments in the United States. The company offers finger print resistant and hard coat protective cover films for various touch enabled devices. It is also involved in developing indium tin oxide less touch films and flexible electronic films for roll to roll printing of flexible thin-film conductor patterns. It sells its products under the Diamond Guard and Clearly Superior brand, as well as under private labels to original equipment manufacturers. The company offers its products for touch panel sensors, cover glass replacements, protective cover films, and antenna and custom circuitry applications. Uni-Pixel, Inc. is headquartered in The Woodlands, Texas.

Uni-Pixel, Inc.

8708 Technology Forest Place Suite 100

The Woodlands, TX 77381 Phone: 281-825-4500 Fax: 281-825-4599

Website: http://www.unipixel.com News:

http://seekingalpha.com/article/1242831-uni-pixel-still-the-best-investment-for-2013?

ZIOP @ $5.61

Sell To Open ZIOP April 2013 $3.00 Put @ Market

Currently .25c bid / .28c time

8.33% return in 32 days

How to do this trade and commentary Video:

(Sign up for Auto-trading and have this trade done for you automatically)

http://youtu.be/DufxqjXbZ1o

ZIOPHARM Oncology, Inc., a biopharmaceutical company, focuses on the development and commercialization of new cancer therapies. Its lead candidate, Palifosfamide (ZIO-201), a potent bi-functional DNA alkylating agent, is under Phase III trial for the treatment of first-line metastatic soft tissue sarcoma, as well as in a pivotal Phase III trial for first-line metastatic small cell lung cancer. The company’s portfolio of clinical-stage product candidates also include IL-12 DNA, which is being tested in a Phase 2 study using synthetic biology to enable controlled, local delivery of therapeutic interleukin-12; Indibulin (ZIO-301), a novel, tubulin binding agent under Phase I/II trial in metastatic breast cancer; and Darinaparsin (ZIO-101), a novel mitochondrial- and hedgehog-targeted agent. In addition, its portfolio comprises various research-stage candidates. The company’s DNA therapeutics are being developed in partnership with Intrexon Corporation through a synthetic biology platform that allows for targeted, controlled production of therapies in humans with a biologic on/off switch. ZIOPHARM Oncology, Inc. was founded in 2003 and is headquartered in New York, New York with operations center located in Boston, Massachusetts.

ZIOPHARM Oncology, Inc.

1180 Avenue of the Americas 20th Floor

New York, NY 10036

Phone: 646-214-0700 Fax: 646-214-0711

Website: http://www.ziopharm.com

News: http://seekingalpha.com/article/1276151-2-biotechs-ready-to-fly?

Remember, no more than 5 or 10% of your portfolio should ever go into any one trade or position.

Step 2: IFit got Put to us, Now we “Lock-in” a profit.
Sell theCovered Call
(Do not buy a stock just to sell the covered Call)
Nothing got “Put” to us last month.
How to do this trade and commentary Video:
(Sign up for Auto-trading and have this trade done for you automatically)
News:
Remember, no more than 5 or 10% of your portfolio should ever go into any one trade or
How did we do last Month?
UNXL @ $27.97
Uni-Pixel, Inc.
Put expired, move to closed positions
$2.6% Return in 1 months
History:
Cost basis $15.00 per share.
Premiums collected: $.40 per share
$2.6% Return in 1 months
$10,000 would have generated $260.00
actual trades:
02/19/2013 Sell To Open UNXL Mar13 $15 Put $0.40
Current/Older Positions/History
This includes a running total for each open position.
Do not enter these positions.
CLSN @ $1.06
Celsion Corporation
Put to us @ $2.00
Hold
Earnings due March 18th
History:

Cost basis $2.00 per share. Premiums collected: $.50 per share $25% Return in 3 months

$10,000 would have generated $2500.00

actual trades:

02/19/2013 Sell To Open CLSN July 2013 $3 Call

(did not fill) 0.00

02/15/2013 Buy CLSN – Option Assignment $2.00

01/22/2013 Sell To Open CLSN Feb13 2 Put $0.30

12/24/2012 Sell To Open CLSN Jan13 2 Put $0.20

Celsion Corporation, an oncology drug development company, engages in the development and commercialization of targeted chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology. The company develops ThermoDox, a liposomal encapsulation of doxorubicin, which is under Phase III clinical trial for primary liver cancer; under phase II clinical trial for colorectal liver metastasis; and under phase II clinical trial for treatment of recurrent chest wall breast cancer. It has a development, product supply, and commercialization agreement with Yakult Honsha Co. for ThermoDox; a license agreement with Duke University to commercialize and use Duke’s thermo-liposome technology; and a joint research agreement with Royal Philips Electronics to evaluate the combination of Philips’ high intensity focused ultrasound with its ThermoDox to determine the potential of this combination to treat various cancers. The company was founded in 1982 and is based in Lawrenceville, New Jersey.

Celsion Corp.

997 Lenox Drive Suite 100

Lawrenceville, NJ 08648 Phone: 609-896-9100 Fax: 609-896-2200

Website: http://www.celsion.com

News: http://seekingalpha.com/article/1261421-celsion-has-multi-bagger-potential-from-here?

CLWR @ $3.21

Called away @$3.00Move to closed positions news:

http://finance.yahoo.com/news/clearwire-sets-annual-lte-target-221841754.html

History:

Cost basis $3.00 per share. Premiums collected: $1.05c per share $35% Return in 17 months

$10,000 would have generated $3500.00 actual trades:

01/22/2013 Sell To Open CLWR Mar13 3 Call $0.20 01/19/2013 CLWR Jan13 5 Call expired

06/18/2012 Sell To Open CLWR Jan13 5 Call $0.05

09/19/2011 Sell To Open CLWR Jan12 4 Call $0.30 09/16/2011 Buy To Close CLWR Sep11 3 Put 09/16/2011 Buy CLWR – Option Assignment $3.00 08/23/2011 Sell To Open CLWR Sep11 3 Put $0.50

Clearwire Corporation, through its subsidiaries, provides fourth generation wireless broadband services in the United States. The company builds and operates mobile broadband networks that offer high-speed mobile Internet and residential Internet access services. It serves retail customers through its CLEAR brand. The company markets its products and services directly to consumers, as well as through cellular retailers, consumer electronics stores, satellite television dealers, and computer sales and repair stores; and through company-operated retail outlets. As of December 31, 2011, it had approximately 1.3 million retail and 9.1 million wholesale subscribers. The company is headquartered in Bellevue, Washington. Clearwire Corporation is a subsidiary of Sprint Hold Co LLC.

News

http://finance.yahoo.com/news/sprints-seals-deal-clearwire-171948629.html

1. DMND @ $16.44

Put to us @ $32.00

Hold

No good options at this time

It looks like the new CEO is turning it around, finally.

3.59% Return

History:

Cost basis $32.00 per share. Premiums collected: 1.15 per share 3.59% Return in 13 months

$10,000 would have generated $359.00 actual trades:

09/24/2012 Sell To Open DMND Dec12 30 Call $0.20

03/20/2012 Sell To Open DMND Jun12 33 Call $0.25 03/18/2012 Buy To Close EXPIRED DMND Mar12 32 CALL 02/21/2012 Sell To Open DMND Mar12 32 Call $0.20 02/17/2012 Buy DMND – Option Assignment $32.00 02/17/2012 Buy To Close DMND Feb12 32 Put

02/06/2012 Sell To Open DMND Feb12 32 Put $1.50

Diamond Foods, Inc. engages in processing, marketing, and distributing snack products. It provides snack products, including roasted, glazed and flavored nuts, trail mixes, dried fruit, seeds, microwave popcorn products, and potato and tortilla chips under the Emerald, Pop Secret, and Kettle brands. The company also offers culinary, in-shell, and ingredient nuts under the Diamond of California brand name. It markets its culinary nuts to individuals who prepare meals or baked goods at home; and ingredient nuts to food processors, restaurants, bakeries, and food service companies and their suppliers. The company sells its products directly to national grocery, mass merchandiser, clubs, convenience stores, and drug store chains in the United States, the United Kingdom, Germany, the Netherlands, Spain, Canada, South Korea, Turkey, China, and Japan. Diamond Foods, Inc. was founded in 1912 and is based in San Francisco, California.

Diamond Foods, Inc.

600 Montgomery Street 13th Floor

San Francisco, CA 94111-2702 Phone: 415-445-7444

Website: http://www.diamondfoods.com

News: http://seekingalpha.com/article/1270231-diamond-in-the-rough-part-iii-post-earnings?

ELN @ $11.78

Hold: ELN April 2013 $12 Call still cooking

History:

Cost basis $12.00 per share. Premiums collected: $1.75 per share 15.41% Return in 8 months

$10,000 would have generated $1541.00

actual trades:

01/22/2013 Sell To Open ELN Apr13 12 Call $0.10

10/22/2012 Sell To Open ELN Jan13 14 Call $0.10

08/20/2012 Sell To Open ELN Oct12 13 Call $0.35

07/23/2012 Sell To Open ELN Aug12 12 Put $1.20

Elan shareholders on the register on December 14, 2012, the record date, received 1 Prothena ordinary share for every 41 Elan ordinary shares or ADSs held.

Elan Corporation, plc operates as a neuroscience-based biotechnology company in the United States, Ireland, and internationally. It engages in research, development, and commercial activities primarily in the areas of Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis (MS). The company offers Tysabri, an alpha -4 integrin inhibitor primarily for the treatment of MS. It is also developing ELND005, a beta amyloid anti-aggregation agent to treat Alzheimer’s disease, which completed Phase II clinical trial. In addition, the company focuses on the discovery and development of antibodies to neo-epitope related targets for the treatment of a range of indications, including amyloidosis, diabetes, cancer, and macular degeneration; and drugs for oncology related diseases comprising NEOD001 for the treatment of AL amyloidosis, as well as focuses on developing ELND005 for bipolar disorder. Further, the company, through collaboration agreement with Biogen Idec, Inc., develops and markets Tysabri for the treatment for Crohn’s disease. Additionally, Elan Corporation, plc, through a 49.9% interest in Janssen AI, develops beta amyloid immunotherapies, including bapineuzumab, ACC-001, and other compounds to treat Alzheimer’s disease.

The company also has collaboration agreements with Cambridge-Elan Centre, Dublin Neurological Institute, University College Dublin, and Proteostasis. Elan Corporation, plc was founded in 1969 and is headquartered in Dublin, Ireland.

Elan Corporation, plc

Treasury Building

Lower Grand Canal Street Dublin, 2

Ireland

Phone: 353 1 709 4000 Fax: 353 1 709 4700

Website: http://www.elan.com

news http://finance.yahoo.com/news/elan-discloses-filing-share-repurchase-174900219.html

FMCN @ $26.10

Focus Media Holding Ltd

Hold: FMCN April 2013 $26 Callstill cooking

Current bid on the buy out is $27.50 History:

Cost basis $ 24.00 per share. Premiums collected: $ 2.30 per share 9.16 % Return in 11 months

$10,000 would have generated $875.00

01/22/2013 Sell To Open FMCN Apr13 27 Call $0.10

10/22/2012 Sell To Open FMCN Jan13 27 Call $0.20

08/14/2012 Buy To Close FMCN Oct12 27 Call -$0.50

07/23/2012 Sell To Open FMCN Oct12 27 Call $0.40

05/21/2012 Sell To Open FMCN Jul12 27 Call$0.40 04/23/2012 Sell To Open FMCN May12 27 Call $0.45 04/20/2012 Buy FMCN – Option Assignment $24.00 04/20/2012 Buy To Close FMCN Apr12 24 Put 03/19/2012 Sell To Open FMCN Apr12 24 Put $1.15

Focus Media Holding Limited, a multi-platform digital media company, operates liquid crystal display (LCD) network using audiovisual digital displays in China. The company engages in selling out-of-home advertising time slots on its network of flat-panel digital advertising displays located in high traffic areas of commercial, residential, and public buildings, such as malls, hotels, and the lobbies of apartment buildings, as well as in-store network. It provides advertising services on poster frames, on screens in movie theatres, and on traditional outdoor billboards. As of December 31, 2011, the company had a LCD display network of approximately 155,751 flat-panel digital displays in approximately 114 cities; in-store network of approximately 50,076 LCD displays in approximately 1,576 hypermarkets, 217 supermarkets, and 1,008 convenience stores; poster frame network of approximately 445,126 non-digital frames and LCD 1.0 picture frame devices, as well as leased screen time in approximately 316 movie theaters, including 2,190 screens. Focus Media Holding Limited is headquartered in Central,Hong Kong.

News: http://seekingalpha.com/article/1167761-6-high-growth-bric-small-and-mid-caps-with-bullish-short-trends?

ONTY @ $2.23

Sell To Open ONTY June 2013 $5 Call @ Market

Currently

.10c bid / .15c time.

How to do this trade and commentary Video:

(Sign up for Auto-trading and have this trade done for you automatically)

http://youtu.be/YFyVBKRNqPc

History:

Cost basis $5.00 per share. Premiums collected: 2.15 per share 43% Return in 14 months

$10,000 would have generated $4300.00 actual trades:

11/19/2012 Sell To Open ONTY Jan13 6 Call $0.55

05/21/2012 Sell To Open ONTY Nov12 7 Call $0.05

03/20/2012 Sell To Open ONTY May12 6 Call $0.05

03/16/2012 Buy ONTY – Option Assignment $5.00 03/16/2012 Buy To Close ONTY Mar12 $5 Put 02/21/2012 Sell To Open ONTY Mar12 $5 Put $0.70

02/19/2012 Buy To Close EXPIRED ONTY FEB12 $5 PUT 01/30/2012 Sell To Open ONTY Feb12 5 Put $0.50 01/22/2012 Buy To Close EXPIRED ONTY JAN12 $5 PUT 01/09/2012 Sell To Open ONTY Jan12 5 Put $0.30

Oncothyreon Inc.(ONTY), a clinical-stage biopharmaceutical company, focuses on the development of therapeutic products for the treatment of cancer. Its primary product candidate, Stimuvax is in Phase III clinical trials for the treatment of non-small cell lung cancer. The company also develops PX-866, a small molecule that is in Phase II trials. In addition, it engages in the preclinical development of ONT-10, a cancer vaccine. The company operates in Canada, the United States, Barbados, and Europe. Oncothyreon Inc. was founded in 1985 and is headquartered in Seattle, Washington.

Oncothyreon Inc

2601 Fourth Avenue Suite 500

Seattle, WA 98121 Phone: 206-801-2100 Fax: 206-801-2101

Website: http://www.oncothyreon.com News:

http://finance.yahoo.com/news/oncothyreon-reports-full-fourth-quarter-120000570.html

PAAS @ $16.71

Hold

there are no good options at this time. History:

Cost basis $36.00 per share. Premiums collected: $3.50 per share Dividends : .19c

Total: $3.64

10.11% Return in 22 months

$10,000 would have generated $1100.00 actual trades:

12/04/2012 PAAS – PAAS QUALIFIED DIVIDEND .125 09/24/2012 Sell To Open PAAS Jan13 40 Call $0.05 01/30/2012Sell To Open PAAS Jul12 36 Call $0.20 12/06/2011 PAAS – PAAS QUALIFIED DIVIDEND $.025 10/24/2011 Sell To Open PAAS Jan12 36 Call $0.40 10/22/2011 Buy To Close EXPIRED PAAS Oct11 36 Call 09/08/2011 PAAS – PAAS QUALIFIED DIVIDEND $.025 06/20/2011 Sell To Open PAAS Oct11 36 Call $0.80 06/19/2011 Buy To Close EXPIRED PAAS JUN11 36 CALL 06/16/2011 PAAS QUALIFIED DIVIDEND $.025 05/23/2011 Sell To Open PAAS Jun11 36 Call $0.50 05/20/2011 Buy PAAS – Option Assignment $36.00 05/20/2011 Buy To Close PAAS May11 36 Put $0.00 04/18/2011 Sell To Open PAAS May11 36 Put $1.55

Pan American Silver Corp. engages in the exploration, development, extraction, processing, production, refining, reclamation, and operation of silver properties. The company also produces and sells gold, zinc, lead, and copper. As of April 27, 2011, it had seven silver mining operations in Mexico, Peru, Argentina, and Bolivia. The company was founded in 1979 and is headquartered in Vancouver, Canada.

Pan American Silver Corp.

625 Howe Street Suite 1500

Vancouver, BC V6C 2T6

Phone: 604-684-1175 Fax: 604-684-0147

Website: http://www.panamericansilver.com

News: http://www.fool.com/investing/general/2013/03/13/has-pan-american-silver-become-the-perfect-stock.aspx

PAY @ $20.71

Hold: PAY July 2013 $43 Call still cooking

History:

Cost basis $43.00 per share. Premiums collected: $3.36 per share 7.63% Return in 20 months

$10,000 would have generated $758.00 actual trades:

10/22/2012 Sell To Open PAY Jan13 44 Call $0.10 06/18/2012 Sell To Open PAY Oct12 $44 Call $0.35 05/21/2012 Sell To Open PAY Jun12 50 Call $1.00 04/16/2012 Sell To Open PAY May12 57.5 Call $1.02 04/16/2012 Buy To Close PAY Apr12 49 Call -$5.36 01/23/2012 Sell To Open PAY Apr12 49 Call $0.40 01/22/2012 Buy To Close EXPIRED PAY JAN12 49 CALL 10/31/2011 Sell To Open PAY Jan12 49 Call $0.90 10/31/2011 Buy To Close PAY Jan12 46 Call -$1.90 10/24/2011 Sell To Open PAY Jan12 46 Call $1.10 10/22/2011 Buy To Close EXPIRED PAY Oct11 42 Call 08/23/2011 Sell To Open PAY Oct11 42 Call $0.60 08/21/2011 Buy To Close EXPIRED PAY AUG11 46 CALL 07/19/2011 Sell To Open PAY Aug11 46 Call $1.05 07/17/2011 Buy To Close EXPIRED PAY JUL11 44 CALL 06/20/2011 Sell To Open PAY Jul11 44 Call $0.75 06/17/2011 Buy To Close PAY Jun11 43 Put $0.00

06/17/2011 Buy PAY – Option Assignment $43.00

05/23/2011 Sell To Open PAY Jun11 43 Put $1.70

VeriFone Systems, Inc. designs, markets, and services electronic payment solutions that enable secure electronic payments among consumers, merchants, and financial institutions worldwide. The company provides countertop electronic payment systems that accept magnetic, smart card, and contactless/radio frequency identification cards; and support credit, debit, check, electronic benefits transfer, and various pre-paid products, as well as offers wireless system solutions. The company also provides products for the point of sale applications, which include displays, user-friendly interfaces, electronic cash registers (ECR) interfaces, durable key pads, and signature capture functionality; and contactless/near field communication (NFC) payment solutions for consumer-activated transactions using contactless cards, tokens, or NFC enabled mobile phones. In addition, it offers various products for petroleum companies, such as integrated electronic payment systems that combine card processing, fuel dispensing, and ECR functions, as well as secure payment systems for integration with petroleum pump controllers and systems. Further, the company provides server-based transaction products; secure payment hardware and software integration modules; and VeriShield Protect, a solution that encrypts and protects consumer card data. Additionally, it offers client services, including payment system consulting, deployment, on-site and telephone-based installation and training, help desk support, repairs, replacement of impaired system solutions, asset tracking, and reporting; and project management services. The company serves financial institutions, payment processors, petroleum companies, retailers, government organizations, and healthcare companies, as well as independent sales organizations. The company was formerly known as VeriFone Holdings, Inc. and changed its name to VeriFone Systems, Inc. in May 2010. The company is headquartered in San Jose, California.

VeriFone Systems, Inc

2099 Gateway Place Suite 600

San Jose, CA 95110 Phone: 408-232-7800 Fax: 408-232-7811

Website: http://www.verifone.com

News: http://beta.fool.com/techjunk13/2013/03/14/can-verifone-systems-walk-the-talk/26961/?source=eogyholnk0000001

QCOR @ $32.36

Questcor Pharmaceuticals, Inc. (QCOR)

Hold: QCOR April 2013 $35 Call still cooking

History:

Cost basis $35.00 per share. Premiums collected: $1.80 per share Dividends:$.40

Total: $2.20

6.28% Return in 7 months

$10,000 would have generated $628.00 actual trades:

01/22/2013 Sell To Open QCOR Apr13 $35 Call $0.55 12/21/2012 QCOR – QCOR QUALIFIED DIVIDEND $.062 12/21/2012 QCOR SUBSTITUTE DIVIDEND PAYMENT $.138 11/19/2012 Sell To Open QCOR Jan13 $35 Call $0.15 11/15/2012 QCOR – QCOR QUALIFIED DIVIDEND $.200 10/22/2012 Sell To Open QCOR Nov12 $38 Call $0.15 09/24/2012 Sell To Open QCOR Oct12 $44 Call $0.05 08/20/2012 Sell To Open QCOR Sep12 $35 Put $0.90

Questcor Pharmaceuticals, Inc., a pharmaceutical company, provides prescription drugs for the treatment of multiple sclerosis, nephrotic syndrome, and infantile spasms indications. It primarily offers H.P. Acthar Gel, an injectable drug for the treatment of acute exacerbations of multiple sclerosis in adults; to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus; and as monotherapy for the treatment of infantile spasms in infants and children under two years of age. The company’s H.P. Acthar Gel also focuses on rheumatology-related conditions, including collagen diseases and rheumatic disorders. In addition, it offers Doral for the treatment of insomnia. The company sells its Acthar primarily to specialty pharmacies; and Doral to pharmaceutical wholesalers. Questcor Pharmaceuticals, Inc. was founded in 1990 and is headquartered in Anaheim, California.

Questcor Pharmaceuticals, Inc.

1300 North Kellogg Drive Suite D

Anaheim, CA 92807 Phone: 714-786-4200 Fax: 714-789-4229

Website: http://www.questcor.com

News:http://www.fool.com/investing/general/2013/03/14/does-questcors-dividend-have-room-to-soar.aspx

TPX @ $45.65

Tempur-Pedic International Inc.

Called away, move to closed positions

History:

Cost basis $40.00 per share. Premiums collected: $1.85 per share Capital gain: $2.00

Total: $3.85

9.62% Return in 9 months

$10,000 would have generated $962.00 actual trades:

02/19/2013 Sell To Open TPX Mar13 42 Call $0.35

12/24/2012 Sell To Open TPX Feb13 $40 Call $0.30

09/24/2012 Sell To Open TPX Dec12 43 Call $0.20

06/18/2012 Sell To Open TPX Sep12 41 Call $0.05

06/16/2012 Buy TPX – Option Assignment $40.00

05/21/2012 Sell To Open TPX Jun12 40 Put $0.95

Tempur-Pedic International Inc. engages in the manufacture, marketing, and distribution of bedding products in North America and internationally. It offers mattresses, pillows, and adjustable bed bases, as well as various cushions and other comfort products. The company sells its products under the TEMPUR and Tempur-Pedic brand names through furniture and bedding retailers, and non-spring and department stores; direct response program, Internet, and company-owned stores; hospitals, nursing homes, healthcare professionals, and medical retailers; and third party distributors. Tempur-Pedic International Inc. was founded in 1989 and is headquartered in Lexington, Kentucky.

Tempur Pedic International Inc.

1713 Jaggie Fox Way

Lexington, KY 40511

Phone: 800-878-8889 Fax: 859-514-4422

Website: http://www.tempurpedic.com

TRGT @ $4.52

Hold

Take no action

There is no good option interest at this time. History:

Cost basis $12.50 per share. Premiums collected: $2.25 per share 18% Return in 17 months

$10,000 would have generated $1800.00 actual trades:

02/21/2012 Sell To Open TRGT May12 15 Call $0.25

11/28/2011 Sell To Open TRGT Feb12 15 Call $0.40 11/18/2011 Buy To Close TRGT Nov11 12.5 Put 11/18/2011 Buy TRGT – Option Assignment $12.50 10/23/2011 Sell to Open TRGT Nov 11 $12.50 PUT $1.60

Targacept, Inc., a biopharmaceutical company, engages in the design, discovery, and development of novel Neuronal Nicotinic Receptors (NNR) Therapeutics for the treatment of diseases and disorders of the nervous system. Its lead program, TC-5214, a nicotinic channel modulator, is in Phase 3 clinical trials as an adjunct treatment for major depressive disorder (MDD) and in Phase 2b clinical trial for switch monotherapy in patients with MDD. The company s novel small molecule product candidates under Phase 2 clinical development include TC-5619 for treating negative symptoms and cognitive dysfunction in schizophrenia, attention deficit/hyperactivity disorder, and Alzheimer s disease; AZD3480 as a treatment for mild to moderate Alzheimer s disease; AZD1446 as a treatment for Alzheimer s disease; and TC-6987 for the treatment of inflammatory disorders, including asthma and Type 2 diabetes. It has a collaborative research and license agreement with AstraZeneca AB for the development and commercialization of AZD3480, TC-5214, and TC-5619; and a product development and commercialization agreement with SmithKline Beecham Corporation to discover, develop, and market product candidates that selectively target specified NNR subtypes in specified therapeutic focus areas. The company was founded in 1997 and is based in Winston-Salem, North Carolina.

Targacept, Inc.

200 East First Street Suite 300

Winston-Salem, NC 27101-4165 Phone: 336-480-2100

Fax: 336-480-2107

Website: http://www.targacept.com

News:

next earnings is April 29th

http://seekingalpha.com/article/1276441-insider-buying-trends-are-these-cash-rich-companies-ready-to-rally?

ZNGA @ $3.62Hold

Take no action

There is no good option interest at this time. History:

Cost basis $14.00 per share. Premiums collected: $2.05 per share 14.64% Return in 13 months

$10,000 would have generated $1464.00 actual trades:

03/19/2012 Sell To Open ZNGA Apr12 16 Call $0.20 03/18/2012 Buy To Close EXPIRED ZNGA MAR12 15 CALL 02/21/2012 Sell To Open ZNGA Mar12 15 Call $0.40 02/17/2012 Buy ZNGA – Option Assignment $14.00 02/17/2012 Buy To Close ZNGA Feb12 14 Put

02/06/2012Sell To Open ZNGA Feb12 14 Put$1.55

Zynga Inc. develops, markets, and operates online social games as live services on the Internet, social networking sites, and mobile platforms. The company offers its online social games under the CityVille, Zynga Poker, FarmVille, CastleVille, FrontierVille, Mafia Wars, Word with Friends, Hidden Chronicles, Zynga Bingo, Scramble With Friends, Slingo, and Dream Heights names. Its games are available on various platforms, including Facebook and other social networks, as well as mobile platforms, such as Apple iOS and Google Android worldwide. The company was formerly known as Zynga Game Network Inc. and changed its name to Zynga Inc. in November 2010.

Zynga Inc. was founded in 2007 and is headquartered in San Francisco, California.

Zynga, Inc.

699 Eighth Street

San Francisco, CA 94103 Phone:855-449-9642 Fax:302-636-5454

Website: http://www.zynga.com

News:

Quote of the Month:

“Your premium brand had better be delivering something special, or it’s not going to getthe business “

~Warren Buffet

Happy New Year!

Until Next Time

Brad Lee

The Options Oracle

https://theoptionsoracle.com/

Ask The Oracle
webinar Sunday 8
pm EST to explain this
newsletter, or other questions
you might have.
Here is the link
http://www.anymeeting.com/MoneyMedic1
There is no preregistration.
Summary:
Sell To Open EXAS
April 2013 $7.00 Put @
Market
Sell To Open UNXL
April 2013 $22.50 Put
@ Market
Sell To Open ZIOP
April 2013 $3.00 Put @
Market
Sell To Open ONTY
June 2013 $5 Call @
Market
Called away:
CLWR @ $3.00 for
a 35% gain
TPX @ $42.00 for
a 9.62% gain
Past performance click
here
https://theoptionsoracle.com/past-performances/
Company News
Military discounts are here!
Thank you for your service!
Refer a Friend
Our unadvertised “refer a
friend” program is going live.
Email us for details.
Disclosure: These are my
actual trades.
I am not telling you what to
do, I am showing you what I
am doing.
Your subscription fee may
be 100% TAX
DEDUCTIBLE if used for
educational
business/investment
purposes. Check with your
Company News
Auto Trading is now active!
Don’t want to be bothered
doing the trades?
Auto-trading is for you. Your
account will automatically do
whatever I do.
You are still in control, you
set the limits either a dollar
amount or a percentage.
Go to the main site, the Auto-
trade link is on the site
https://theoptionsoracle.com/auto-trading/
We will be doing a webinar
Sunday 8 pm est to explain
this newsletter.
Here is the link
http://www.anymeeting.com/MoneyMedic1
Disclosure: These are my
actual trades.
Your subscription fee may
be 100% TAX
DEDUCTIBLE if used for
educational
business/investment
purposes. Check with your Licensed
Professional adviser
Options involve risk and are
not suitable for all investors.
Prior to trading options, you
must be approved for
options trading and read
the Characteristics and
Risks of Standardized
Copies of this document may
also be obtained from your
broker, from any exchange on
which options are traded, by
placing an order online, or by
contacting the Options
Clearing Corporation directly
at 1 N. Wacker Dr., Suite
500, Chicago, IL 60606. (1-
888-678-4667).
Brad Lee AKA “The Options
Oracle” and “The Money
Medic” is an individual
investor who does not
manage money for any
financial institution. You are

purchasing the list of stocks that he uses to select options contracts he feels will return him the highest, safest profits. Brad is not a broker, or financial adviser. He is a remarkable investor who has developed a successful strategy for himself, and is willing to share some of his magic with you. We urge you to paper trade these picks and learn how to develop a strategy that is appropriate for you. Thank You.

We make no recommendations on investment and we do not provide financial, tax or legal advice. Content and tools are provided for educational and informational purposes only.

Disclaimer

Trading or investment in stocks, futures & options, and commodity are subject to potential market risks. You can use our materials or recommendations for educational purposes, this is not intended as Trading or Investment advice. We are not financial advisers. We cannot provide any advice as to whether or not options or our trading ideas are suitable investments for your particular financial situation. We are in the business of publishing our trade ideas for market analysis only. We highly recommend that our subscribers review their trading allocation with a qualified registered financial adviser/planner. Legal Disclaimer: we do not exist to render and do not give legal, tax, economic or investment advice and disclaims all liability for the actions or inaction taken or not as a result of communications from or to its members, officers, directors, employees and contractors. Each individual should consult his/her own counsel, accountant and other advisors as to legal, tax, economic, investment and related matters concerning any type of investments.

This email and any files transmitted with it are solely intended for the use of the addressee(s) and may contain information that is confidential and privileged. If you receive this email in error, please advise us by return email immediately. Please also disregard the contents of the email, delete it and destroy any copies immediately.